250 related articles for article (PubMed ID: 9973447)
1. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.
Weinberg AD; Wegmann KW; Funatake C; Whitham RH
J Immunol; 1999 Feb; 162(3):1818-26. PubMed ID: 9973447
[TBL] [Abstract][Full Text] [Related]
2. OX-40: life beyond the effector T cell stage.
Weinberg AD; Vella AT; Croft M
Semin Immunol; 1998 Dec; 10(6):471-80. PubMed ID: 9826580
[TBL] [Abstract][Full Text] [Related]
3. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
Gramaglia I; Weinberg AD; Lemon M; Croft M
J Immunol; 1998 Dec; 161(12):6510-7. PubMed ID: 9862675
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system.
Körner H; Lemckert FA; Chaudhri G; Etteldorf S; Sedgwick JD
Eur J Immunol; 1997 Aug; 27(8):1973-81. PubMed ID: 9295034
[TBL] [Abstract][Full Text] [Related]
6. The immunopathology of acute experimental allergic encephalomyelitis induced with myelin proteolipid protein. T cell receptors in inflammatory lesions.
Sobel RA; Kuchroo VK
J Immunol; 1992 Aug; 149(4):1444-51. PubMed ID: 1380045
[TBL] [Abstract][Full Text] [Related]
7. OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis.
Weinberg AD; Lemon M; Jones AJ; Vainiene M; Celnik B; Buenafe AC; Culbertson N; Bakke A; Vandenbark AA; Offner H
J Neurosci Res; 1996 Jan; 43(1):42-9. PubMed ID: 8838572
[TBL] [Abstract][Full Text] [Related]
8. MRC OX-2 defines a novel T cell costimulatory pathway.
Borriello F; Lederer J; Scott S; Sharpe AH
J Immunol; 1997 May; 158(10):4548-54. PubMed ID: 9144466
[TBL] [Abstract][Full Text] [Related]
9. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein.
Higgins LM; McDonald SA; Whittle N; Crockett N; Shields JG; MacDonald TT
J Immunol; 1999 Jan; 162(1):486-93. PubMed ID: 9886424
[TBL] [Abstract][Full Text] [Related]
10. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
[TBL] [Abstract][Full Text] [Related]
11. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.
Racke MK; Scott DE; Quigley L; Gray GS; Abe R; June CH; Perrin PJ
J Clin Invest; 1995 Nov; 96(5):2195-203. PubMed ID: 7593605
[TBL] [Abstract][Full Text] [Related]
12. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes.
Tan L; Gordon KB; Mueller JP; Matis LA; Miller SD
J Immunol; 1998 May; 160(9):4271-9. PubMed ID: 9574529
[TBL] [Abstract][Full Text] [Related]
13. Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
Weinberg AD; Rivera MM; Prell R; Morris A; Ramstad T; Vetto JT; Urba WJ; Alvord G; Bunce C; Shields J
J Immunol; 2000 Feb; 164(4):2160-9. PubMed ID: 10657670
[TBL] [Abstract][Full Text] [Related]
14. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis.
Perrin PJ; June CH; Maldonado JH; Ratts RB; Racke MK
J Immunol; 1999 Aug; 163(3):1704-10. PubMed ID: 10415078
[TBL] [Abstract][Full Text] [Related]
16. Evidence that Fas and FasL contribute to the pathogenesis of experimental autoimmune encephalomyelitis.
Dittel BN
Arch Immunol Ther Exp (Warsz); 2000; 48(5):381-8. PubMed ID: 11140465
[TBL] [Abstract][Full Text] [Related]
17. Experimental allergic encephalomyelitis (EAE) in mice lacking CD4+ T cells.
Koh DR; Ho A; Rahemtulla A; Penninger J; Mak TW
Eur J Immunol; 1994 Sep; 24(9):2250-3. PubMed ID: 7916298
[TBL] [Abstract][Full Text] [Related]
18. CD4+ICOS+ T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'.
Rojo JM; Pini E; Ojeda G; Bello R; Dong C; Flavell RA; Dianzani U; Portolés P
Int Immunol; 2008 Apr; 20(4):577-89. PubMed ID: 18310064
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation of CNS-specific effector and regulatory T cells during tolerance induction by recombinant invariant chains in vivo.
Lange C; Doster H; Steinbach K; Kalbacher H; Scholl M; Melms A; Bischof F
Brain Behav Immun; 2009 Aug; 23(6):861-7. PubMed ID: 19362139
[TBL] [Abstract][Full Text] [Related]
20. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice.
Tran EH; Hoekstra K; van Rooijen N; Dijkstra CD; Owens T
J Immunol; 1998 Oct; 161(7):3767-75. PubMed ID: 9759903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
